Meningococcal Vaccine Development To Get FDA Advisory Cmte. Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Although it's announced as a scientific discussion on immunological markers, the April 6 meeting will have large implications for Menveo and Menactra's applications to expand their indications into infants.
You may also be interested in...
Novartis’ Expansion Of Menveo Further Set Back By “Complete Response”
FDA issues “complete response” for an sBLA that would expand use of Novartis’ meningitis vaccine in children aged two months to 24 months, which could have offered a competitive advantage against Sanofi’s market-leading Menactra.
Expanded Label For Sanofi Pasteur's Menactra May Lead To Only Limited Market
FDA has extended approval of the meningococcal disease vaccine to children as young as nine months, but if the CDC recommends it only for high-risk groups the expanded market could be limited.
Expanded Label For Sanofi Pasteur's Menactra May Lead To Only Limited Market
FDA has extended approval of the meningococcal disease vaccine to children as young as nine months, but if the CDC recommends it only for high-risk groups the expanded market could be limited.